Press Release
Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting
- Rapid and significant reduction in skin lesions, 66% (p<0.001) and 76% (p<0.001) mean reduction in EASI score in 4 and 7 weeks, respectively.
- Rapid and significant resolution of worst itch and pain, 57% (p<0.001) and 61% (p<0.001) mean reduction within 4 weeks, respectively.
- Substantial mean reduction of worst itch and pain 71% (p<0.001) and 84% (p<0.001) within 7 weeks, respectively.
The results being presented by Dr. Simpson demonstrate that bermekimab treatment resulted in rapid and significant improvement of disease in patients with moderate-to-severe AD. After only 7 weeks of treatment, 71% of patients that received a 400mg bermekimab weekly regimen had at least 75% reduction in their disease, as measured by the Eczema Area and Severity Index (EASI) score (this compares to 44-51% of patients achieving 75% improvement in EASI score after 16 weeks therapy as reported for two Phase III clinical trials for the existing
In the study, 38 patients in two treatment groups received a low (200mg) or high (400mg) dose of bermekimab once weekly for either a 4 or 7-week treatment regimen, respectively. There was statistically and clinically significant improvement in treatment response for key measures of disease severity in the high dose versus the low dose group.
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
About XBiotech
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our
Contact
aotero@xbiotech.com
512-386-2930